Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine, FT says
Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine, FT says
ReutersSun, March 29, 2026 at 11:15 AM UTC
0
A drone view shows the Eli Lilly logo on one of the company’s offices in San Diego, California, U.S., November 21, 2025. REUTERS/Mike Blake
March 29 (Reuters) - Eli Lilly will sign a $2 billion deal with Hong Kong-listed biotech Insilico Medicine, which uses artificial intelligence for drug discovery, the Financial Times reported on Sunday.
Lilly will acquire exclusive rights to sell a GLP-1 drug for diabetes from Insilico Medicine, the FT report said, citing sources familiar with the matter.
Advertisement
Reuters could not immediately verify the report.
(Reporting by Rishabh Jaiswal in Bengaluru. Editing by Mark Potter)
Source: “AOL Breaking”
